drugset / Trial / NCT07850752
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of disease progression.
Timeline
- Start
- 2026-12-01
- Primary completion
- 2028-09-17
- Completion
- 2030-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atrasentan | Other / unclassified | — | — |
| Background | zigakibart | Monoclonal antibody | — | — |